Peritoneal transport of cefonicid

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Cefonicid is an expanded-spectrum cephalosporin with high protein binding.
• Continuous ambulatory peritoneal dialysis (CAPD) alters drug pharmacokinetics due to fluid shifts and altered clearance.
• Understanding cefonicid's behavior in CAPD is crucial for effective infection management.

Purpose of the Study:

• To characterize the pharmacokinetics of cefonicid in CAPD patients.
• To determine cefonicid serum and peritoneal fluid concentrations over time.
• To provide dosage recommendations for cefonicid in CAPD.

Main Methods:

• Six noninfected, stable CAPD patients received a 1.0-g intravenous dose of cefonicid.
• Serum and peritoneal fluid (dialysate) concentrations were measured over 72 hours.
• Pharmacokinetic parameters including half-life, clearance, and volume of distribution were calculated.

Main Results:

• Mean serum cefonicid concentrations were 105 ± 25 µg/ml at 3h and 35.6 ± 14.4 µg/ml at 72h.
• The drug exhibited a prolonged serum half-life of 49.7 ± 18 hours.
• Peritoneal fluid concentrations were low, averaging 2.7 µg/ml over 72 hours.

Conclusions:

• Cefonicid demonstrates a significantly prolonged half-life in CAPD patients.
• Low penetration into peritoneal fluid suggests potential challenges for treating peritoneal infections with standard dosing.
• Dosage adjustments and careful clinical consideration are necessary for cefonicid use in CAPD patients.